...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Gemcitabine/carboplatin in advanced non-small cell lung cancer.
【24h】

Gemcitabine/carboplatin in advanced non-small cell lung cancer.

机译：吉西他滨/卡铂在晚期非小细胞肺癌。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Gemcitabine/cisplatin is among the most widely used regimens in Europe for first-line treatment of non-small cell lung cancer (NSCLC). Problems with cisplatin use in this setting include significant nonhematologic toxicity and difficulty of use in outpatients. Carboplatin constitutes a reasonable alternative to cisplatin in this combination, since it shows synergy with gemcitabine in vitro, is easier to use in ambulatory patients, and has a better nonhematologic toxicity profile. Studies of gemcitabine/cisplatin on a 28-day schedule (gemcitabine on days 1, 8, 15 and carboplatin on day 1) generally indicate excessive thrombocytopenia. Use of a 21-day schedule (e.g. gemcitabine on days 1 and 8, carboplatin on day 1) is associated with reduced toxicity and comparable efficacy. Results of one randomized phase II study suggest reduced toxicity and reduced objective response rate with gemcitabine/carboplatin versus gemcitabine/cisplatin. We are currently conducting a phase III comparison of gemcitabine 1200 mg/m(2) on days 1 and 8 plus carboplatin at an area under the curve of 5 mg/ml/min on day 1 versus gemcitabine at the same dose plus cisplatin 80 mg/m(2) on day 1 every 21 days in chemotherapy-nai;ve patients with stage IIIB/IV NSCLC; interim analysis indicates comparable response rates (47 and 48%). A better understanding of the relative toxicities of these regimens should be provided by the final results of this trial.
机译：吉西他滨/顺铂是最广泛之一用于一线治疗方案在欧洲非小细胞肺癌(NSCLC)。与顺铂在此设置包括使用重大nonhematologic毒性和困难在门诊病人中使用。构成一个合理的替代顺铂在这个组合中,因为它显示了协同作用吉西他滨在体外,更容易使用门诊病人,和有一个更好的nonhematologic毒性。吉西他滨/顺铂在28天的日程安排(吉西他滨在天1、8、15和卡铂天1)通常表明过度血小板减少症。吉西他滨在第1和8天,卡铂1)与毒性和减少有关类似的功效。第二阶段研究表明毒性和减少减少客观缓解率gemcitabine / carboplatin与吉西他滨/顺铂。进行第三阶段的比较吉西他滨1200毫克/米(2)天1和8 +卡铂曲线下面积5毫克/毫升/分钟的第一天在同一剂量与吉西他滨+顺铂80毫克/天(2)1每21天chemotherapy-nai;第四阶段希望/患者非小细胞肺癌;反应率(47岁,48%)。理解这些的相对毒性方案应提供的最终结果这个试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号